Risk Stratification Value of Biomarkers in Patients With Ventricular Arrhythmias (FUTURE): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- Change in the incidence of MACCE
研究概览
简要总结
The investigation of biomarkers for immune status and metabolic state, as well as host microbiota composition, in patients with ventricular arrhythmias before and after radiofrequency ablation, can provide new insights for specific and personalized treatment. This can help establish early prediction and prognosis models and provide a basis for clinically effective diagnosis and treatment.
详细描述
Abnormal immune and metabolic states can lead to the occurrence of various systemic diseases, including the development of cardiovascular diseases through multiple mechanisms. On the other hand, various diseases can also feedback and regulate the immune and metabolic systems. However, currently there is no research on the impact of immune and metabolic states on ventricular arrhythmia. Exploring the biomarker characteristics and risk stratification of patients with ventricular arrhythmias undergoing radiofrequency ablation before and after the procedure can provide new insights for specific and personalized treatment. It can establish early prediction and prognostic models, providing evidence for clinically effective diagnosis and treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with ventricular premature beats, ventricular tachycardia, or ventricular fibrillation detected by regular surface twelve-lead electrocardiogram or Holter.
排除标准
- •Age <18 or >80 years old;
- •Patients with autoimmune diseases or immune deficiencies, or those who have used immunosuppressive or immune modulating agents in the past 3 months;
- •Platelet count <100×10^9/L or functional platelet defects;
- •Congenital or acquired coagulation or bleeding disorders;
- •Patients with a history of organ transplantation or are preparing to receive organ transplantation;
- •Unwilling to sign an informed consent or cooperate with the examination.
结局指标
主要结局
Change in the incidence of MACCE
时间窗: 3,6 months,1,3,5 years after enrollment.
Major adverse cardiovascular and cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
次要结局
- Change in the incidence of vessel revascularization(3,6 months,1,3,5 years after enrollment.)
- Change in the incidence of all-cause death(3,6 months,1,3,5 years after enrollment.)
- Change in the incidence of myocardial infarction(3,6 months,1,3,5 years after enrollment.)
- Change in the incidence of stroke(3,6 months,1,3,5 years after enrollment.)